Treatment of Shugan Hewei recipe in the treatment of gastroesophageal reflux disease (GERD)

Submission date	Recruitment status	Prospectively registered
24/03/2015	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
08/04/2015	Completed	[X] Results
Last Edited	Condition category	[] Individual participant data
17/05/2023	Digestive System	

Plain English summary of protocol

Background and study aims

Gastro-oesophageal reflux disease (GORD) is a common condition where acid from the stomach leaks out of the stomach and up into the oesophagus (gullet). Some patients' symptoms persist despite treatment with drugs. This study aims to see whether Shugan Hewei recipe might help those with GERD. Previous studies have suggested a benefit but this needs confirmation.

Who can participate?

Patients diagnosed by their doctors as having gastroesophageal reflux disease (GERD).

What does the study involve?

Participants will be randomly allocated to take either Shugan Hewei recipe herbal granules and a placebo (dummy) tablet for 4 weeks, or an Omeprazole tablet and placebo granules for 4 weeks.

What are the possible benefits and risks of participating?

We are hoping that towards the end of the 4-week period reflux and heartburn will improve. The drugs have been used for many years and the side effects are well recognised. Only a very few will not tolerate the drug because of stomach discomfort, dryness of the mouth, constipation, diarrhoea, nausea, rash or dizziness.

Where is the study run from?

- 1. Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University
- 2. Peking Union Medical College Hospital
- 3. Beijing Shijitan Hospital
- 4. Shengjing Hospital of China Medical University

When is the study starting and how long is it expected to run for? From April 2015 to September 2017.

Who is funding the study?

Beijing Municipal Administration of Hospitals (China).

Who is the main contact? Dr Shengsheng Zhang zhss2000@163.com

Contact information

Type(s)

Scientific

Contact name

Dr Luqing Zhao

ORCID ID

http://orcid.org/0000-0003-1986-3511

Contact details

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University No. 23 Meishuguan Back Street Dongcheng District Beijing China 100010

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Efficacy of Shugan Hewei recipe in the treatment of gastroesophageal reflux disease (GERD): a multicentre parallel-group randomised controlled trial

Study objectives

The purpose of the trial is to define the clinical benefit of Shugan Hewei recipe in gastroesophageal reflux disease (GERD). The primary endpoint is to assess the effect of Shugan Hewei recipe on GERD questionnaire Score.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics committee of Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 03/07/2015, NO.2015BL-007-02

Study design

Multicentre parallel-group double-blind randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Gastroesophageal reflux disease (GERD)

Interventions

Participants will be randomized to receive either:

- 1. Shugan Hewei recipe herbal granules and matching Omeprazole placebo tablet for 4 weeks or
- 2. Omeprazole tablet and matching Shugan Hewei recipe herbal placebo granules for 4 weeks.

Herbal granules were dissolved in 300 ml of boiled water, 150 ml twice daily. Omeprazole tablet 20 mg once a day, on an empty stomach.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Omeprazole, Shugan Hewei recipe herbal granules

Primary outcome measure

GERD questionnaire score, measured at baseline, 2 weeks and 4 weeks

Secondary outcome measures

- 1. Traditional Chinese Medicine syndromes of IBS score, measured at baseline, 2 weeks and 4 weeks
- 2. High resolution manometry (HRM), measured at baseline and 4 weeks

Overall study start date

01/04/2015

Completion date

30/09/2017

Eligibility

Key inclusion criteria

- 1. Patients with GERD, GERD questionnaire score >8
- 2. Patients able to give informed consent
- 3. Female patients of childbearing potential who are willing to use at least one highly effective contraceptive method
- 4. Aged 18-65 years, either sex

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

65 Years

Sex

Both

Target number of participants

288

Total final enrolment

288

Key exclusion criteria

- 1. Women who are pregnant or breastfeeding
- 2. Patients with Zollinger-Ellison syndrome or primary esophageal dynamic disease
- 3. Patients with serious concomitant diseases e.g. cardiovascular, renal, hepatic, respiratory, neurological, endocrine, hematopoietic etc
- 4. Patients with early warning symptoms of malignant tumors
- 5. Patients who were taking proton-pump inhibitor or H2 receptor antagonist during the prior 2 weeks
- 6. Patients who have allergic constitution or known to be allergic to the drug used in this trial
- 7. Patients who are involved in other trials
- 8. Patients with poor compliance or other reasons that the researcher considered not to be appropriate to participate in this trial

Date of first enrolment

01/04/2015

Date of final enrolment

Locations

Countries of recruitment

China

Study participating centre

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University

Beijing China

100010

Study participating centre Peking Union Medical College Hospital

Beijing China 100032

Study participating centre Beijing Shijitan Hospital

Beijing China

Study participating centre Shengjing Hospital of China Medical University

Shenyang China

_

Sponsor information

Organisation

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

Sponsor details

No. 23 Meishuguan Back Street Dongcheng District Beijing China 100010

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/057vq6e26

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Beijing Municipal Administration of Hospitals

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Available on request

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Results article28/07/202117/05/2023YesNo